title: Prostate cancer immunotherapy.
abstract: The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.
authors.affiliation: Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. kmay1@partners.org
authors.forename: Kenneth F
authors.initials: KF
authors.lastname: May
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: Charles G
authors.initials: CG
authors.lastname: Drake
authors.forename: Glenn
authors.initials: G
authors.lastname: Dranoff
authors.forename: Philip W
authors.initials: PW
authors.lastname: Kantoff
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D000074324:Ipilimumab; D008297:Male; D051379:Mice; D018448:Models, Immunological; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor; D014020:Tissue Extracts; C511774:sipuleucel-T